Karen S. Acker

Array ( [id] => 16189407 [patent_doc_number] => 20200230256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => CAPPED AND UNCAPPED ANTIBODY CYSTEINES, AND THEIR USE IN ANTIBODY-DRUG CONJUGATION [patent_app_type] => utility [patent_app_number] => 16/807375 [patent_app_country] => US [patent_app_date] => 2020-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9055 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16807375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545338 [patent_doc_number] => 11718678 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Method for altering plasma retention and immunogenicity of antigen-binding molecule [patent_app_type] => utility [patent_app_number] => 16/806027 [patent_app_country] => US [patent_app_date] => 2020-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 65 [patent_no_of_words] => 114620 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 222 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16806027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18281352 [patent_doc_number] => 20230096824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/434315 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17434315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268865 [patent_doc_number] => 20200270352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/801491 [patent_app_country] => US [patent_app_date] => 2020-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16801491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16190824 [patent_doc_number] => 20200231673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/799662 [patent_app_country] => US [patent_app_date] => 2020-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 254 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16799662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090497 [patent_doc_number] => 20200199235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => ANTI-HUMAN CD69 ANTIBODY, AND USE THEREOF FOR MEDICAL PURPOSES [patent_app_type] => utility [patent_app_number] => 16/796481 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14375 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16796481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18398223 [patent_doc_number] => 11660339 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-30 [patent_title] => Methods of treating cancer using compositions of antibodies and carrier proteins with antibody pretreatment [patent_app_type] => utility [patent_app_number] => 16/792777 [patent_app_country] => US [patent_app_date] => 2020-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 8508 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16792777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398231 [patent_doc_number] => 20220040321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATES WITH IMPROVED HOMOGENEITY [patent_app_type] => utility [patent_app_number] => 17/430494 [patent_app_country] => US [patent_app_date] => 2020-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993397 [patent_doc_number] => 20200172569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => METHOD FOR PREPARING A COMPOSITION COMPRISING HIGHLY CONCENTRATED ANTIBODIES BY ULTRAFILTRATION [patent_app_type] => utility [patent_app_number] => 16/782493 [patent_app_country] => US [patent_app_date] => 2020-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993475 [patent_doc_number] => 20200172608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF [patent_app_type] => utility [patent_app_number] => 16/779028 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25761 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16779028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931163 [patent_doc_number] => 20200157215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => ANTIBODY MOLECULES WHICH BIND CD22 [patent_app_type] => utility [patent_app_number] => 16/778523 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61994 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 289 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16778523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16252223 [patent_doc_number] => 20200261597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => BIOFUNCTIONALIZED NANOPARTICLES AND USES THEREOF IN ADOPTIVE CELL THERAPY [patent_app_type] => utility [patent_app_number] => 16/776642 [patent_app_country] => US [patent_app_date] => 2020-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18647 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16776642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16190854 [patent_doc_number] => 20200231703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => TREATMENT OF OCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 16/751824 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16310926 [patent_doc_number] => 20200289664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS [patent_app_type] => utility [patent_app_number] => 16/748496 [patent_app_country] => US [patent_app_date] => 2020-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16748496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102466 [patent_doc_number] => 11542342 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Binding molecules with modified J-chain [patent_app_type] => utility [patent_app_number] => 16/745059 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 46083 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16745059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18604697 [patent_doc_number] => 11746147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Angiopoietin 2, VEGF dual antagonists [patent_app_type] => utility [patent_app_number] => 16/741686 [patent_app_country] => US [patent_app_date] => 2020-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 16726 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16741686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102458 [patent_doc_number] => 11542333 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Compositions for increasing half-life of a therapeutic agent in canines and methods of use [patent_app_type] => utility [patent_app_number] => 16/733105 [patent_app_country] => US [patent_app_date] => 2020-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 54 [patent_no_of_words] => 18720 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 192 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16733105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253552 [patent_doc_number] => 20200262926 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => MULTISPECIFIC BINDING PROTEINS WITH MUTANT FAB DOMAINS [patent_app_type] => utility [patent_app_number] => 16/725228 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16725228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437121 [patent_doc_number] => 20200354447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION [patent_app_type] => utility [patent_app_number] => 16/725694 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16725694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18590277 [patent_doc_number] => 11739160 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => PseudoFab-based multispecific binding proteins [patent_app_type] => utility [patent_app_number] => 16/725224 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 32 [patent_no_of_words] => 34319 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16725224 [rel_patent_id] =>[rel_patent_doc_number] =>)